NASDAQ:MBVX - Mabvax Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.34 -0.01 (-2.86 %)
(As of 02/18/2019 04:00 PM ET)
Previous Close$0.3501
Today's Range$0.2610 - $0.3836
52-Week Range$0.1025 - $2.60
Volume6,492 shs
Average Volume27,028 shs
Market Capitalization$3.15 million
P/E RatioN/A
Dividend YieldN/A
MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.

Receive MBVX News and Ratings via Email

Sign-up to receive the latest news and ratings for MBVX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MBVX
Previous SymbolOTCMKTS:TELKD



Sales & Book Value

Annual SalesN/A



Market Cap$3.15 million
OptionableNot Optionable

Mabvax Therapeutics (NASDAQ:MBVX) Frequently Asked Questions

What is Mabvax Therapeutics' stock symbol?

Mabvax Therapeutics trades on the NASDAQ under the ticker symbol "MBVX."

When did Mabvax Therapeutics' stock split? How did Mabvax Therapeutics' stock split work?

Mabvax Therapeutics shares reverse split on Friday, February 16th 2018. The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 15th 2018. An investor that had 100 shares of Mabvax Therapeutics stock prior to the reverse split would have 33 shares after the split.

How were Mabvax Therapeutics' earnings last quarter?

Mabvax Therapeutics Holdings Inc (NASDAQ:MBVX) issued its earnings results on Tuesday, November, 7th. The company reported ($1.62) earnings per share for the quarter. View Mabvax Therapeutics' Earnings History.

When is Mabvax Therapeutics' next earnings date?

Mabvax Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Mabvax Therapeutics.

Has Mabvax Therapeutics been receiving favorable news coverage?

News headlines about MBVX stock have been trending positive recently, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mabvax Therapeutics earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.

Who are some of Mabvax Therapeutics' key competitors?

Who are Mabvax Therapeutics' key executives?

Mabvax Therapeutics' management team includes the folowing people:
  • Mr. John David Hansen, Chairman, Pres & CEO (Age 67)
  • Prof. Philip O. Livingston, Co-Founder, Chief Science Officer & Director (Age 75)
  • Mr. Gregory P. Hanson C.M.A., M.B.A., MBA, CMA, Chief Financial Officer (Age 71)
  • Dr. Paul W. Maffuid, Exec. VP of R&D (Age 63)
  • Dr. Paul F. Resnick, VP & Chief Bus. Officer (Age 61)

How do I buy shares of Mabvax Therapeutics?

Shares of MBVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mabvax Therapeutics' stock price today?

One share of MBVX stock can currently be purchased for approximately $0.34.

How big of a company is Mabvax Therapeutics?

Mabvax Therapeutics has a market capitalization of $3.15 million. Mabvax Therapeutics employs 11 workers across the globe.

What is Mabvax Therapeutics' official website?

The official website for Mabvax Therapeutics is

How can I contact Mabvax Therapeutics?

Mabvax Therapeutics' mailing address is 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121. The company can be reached via phone at 858-259-9405 or via email at [email protected]

MarketBeat Community Rating for Mabvax Therapeutics (NASDAQ MBVX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  363
MarketBeat's community ratings are surveys of what our community members think about Mabvax Therapeutics and other stocks. Vote "Outperform" if you believe MBVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by Staff

Featured Article: Tariff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel